EXEL vs NVS
EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | EXEL | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $52.20 | $154.21 | |
| Market cap as of 2026-08-08 | $12.9B | $229.1B | |
| P/E as of 2026-08-08 | 15.83 | 22.17 | EXEL lower |
| PEG as of 2026-08-08 | 1.19 | 3.66 | EXEL lower |
| Net margin as of 2026-08-08 | +35.1% | +22.5% | EXEL higher |
| Gross margin as of 2026-08-08 | +96.4% | +75.0% | EXEL higher |
| Operating margin as of 2026-08-08 | +39.4% | +29.9% | EXEL higher |
| ROE as of 2026-08-08 | +40.2% | +29.9% | EXEL higher |
| ROA as of 2026-08-08 | +30.5% | +11.1% | EXEL higher |
| Debt / equity as of 2026-08-08 | 0.00 | 1.18 | EXEL lower |
| Revenue growth (YoY) as of 2026-08-08 | +7.9% | +3.3% | EXEL higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | n/a | |
| Dividend yield as of 2026-08-08 | n/a | +3.0% | |
| Beta as of 2026-08-08 | 0.47 | 1.19 | |
| 1-year return as of 2026-08-06 close | +38.4% | +35.9% | EXEL higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.